Skip to main content

Table 3 Grade 3-4 non-hemathologic toxicity in 51 patient receiving gemcitabine and docetaxel (GD)

From: Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone

G3-4 non-hemathologic toxicity

Compliance

Outcome

GD cys

Allergic reaction (1st cycle)

Stop docetaxel

Resolved

2

Allergic reaction (1st cycle)

Stop docetaxel

Resolved

4

Allergic reaction (4th cycle)

Stop docetaxel

Resolved

5

Capillary leak syndrome

Stop docetaxel

Resolved

9

Diarrhea

Delay/dose reduction

Resolved

6

Febrile neutropenia

Delay

Resolved

7

Lung fibrosis

None

Resolved

5

Foot syndrome

None

Resolved

2

Stephen Johnson syndrome

Stop docetaxel

Off -treatment

1

  1. GD cys gemcitabine and docetaxel number of chemoteherapy cycles